Crossmark

Benefit–Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism

Crossref DOI link: https://doi.org/10.1007/s40266-025-01192-7

Published Online: 2025-03-31

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dobesh, Paul P. https://orcid.org/0000-0002-2668-7168
Volkl, Albert A.

Pap, Ákos Ferenc

Damaraju, C. V.

Levitan, Bennett

Yuan, Zhong

Amin, Alpesh N.
Funding

Funding for this research was provided by:

Janssen Scientific Affairs
License Information

Text and Data Mining valid from 2025-03-31

Version of Record valid from 2025-03-31
More Information

Article History

Accepted: 17 February 2025

First Online: 31 March 2025

Declarations

:

: This study was funded by Janssen Scientific Affairs, LLC, a Johnson & Johnson Company.

: P.P.D. has served as a consultant for the Pfizer/Bristol Myers Squibb alliance, Janssen Pharmaceuticals, and AstraZeneca. Á.F.P. is an employee of Bayer AG. A.A.V., C.D., B.L., and Z.Y. are employees of Johnson and Johnson. A.N.A. has served as principal investigator or coinvestigator of clinical trials sponsored by NIH/NIAID, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, OctaPharma, Fulcrum Therapeutics, and Alexion; speaker and/or consultant for Pfizer, BMS, Jansen, Portola, Salix, Alexion, AstraZeneca, Bayer, Ferring, Seres, Spero, Eli Lilly, Nova Nordisk, Gilead, Renibus, GSK, Dexcom, Reprieve, HeartRite, and Aseptiscope; unrelated to this manuscript.

: The data sharing policy of Janssen Pharmaceutical Companies of Johnson and Johnson (J&J) is available at . The data supporting the findings of this study may be obtained from the authors, if the request is approvable per the J&J data sharing policy.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below